Top

Published in:

01-09-2020 | Apraxia | Original Communication

Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech

Authors: Zeynep Idil Seckin, Jennifer L. Whitwell, Rene L. Utianski, Hugo Botha, Farwa Ali, Joseph R. Duffy, Heather M. Clark, Mary M. Machulda, Lennon G. Jordan, Hoon-Ki Min, Val J. Lowe, Keith A. Josephs

Published in: Journal of Neurology | Issue 9/2020

Abstract

Objective

To describe ¹²³I-FP-CIT (DAT scan) SPECT findings in progressive apraxia of speech (PAOS) patients and to compare those findings with progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).

Background

PAOS is a neurodegenerative syndrome in which patients present with apraxia of speech, a motor speech disorder affecting programming and planning of speech. Patients with PAOS predictably develop Parkinsonism. DAT scan is a neuroimaging tool that assesses the integrity of presynaptic dopamine transporters in striatum and is usually abnormal in PSP and CBS.

Methods

As part of an NIH-funded grant, we performed a DAT scan on 17 PAOS patients early in the disease course. DaTQUANT software was used to quantify uptake in the left and right caudate and anterior/posterior putamen, with striatum to background ratios (SBRs). The PAOS cohort was compared to 15 PSP and 8 CBS patients.

Results

Five PAOS patients (29%) showed abnormalities in at least one striatal region on DAT scan. When the five PAOS patients with abnormal DAT were compared to the PSP and CBS patients, the only difference observed was lower uptake in the posterior putamen in PSP (p = 0.03). There were no differences is putamen/caudate ratio or in symmetry of uptake, across all groups. There was also no difference in MDS-UPDRS-III scores between PAOS patients with and without abnormal DAT scans (p = 0.56).

Conclusions

Abnormal DAT scan is observed early in the disease course in approximately 30% of PAOS patients, with striatal abnormalities similar to those in PSP and CBS.

McNeil MR, Robin DA, Schmidt RA (2009) Apraxia of speech: definition and differential diagnosis. Clin Manag Sens Speech Disord 2:249–267

Josephs KA et al (2014) The evolution of primary progressive apraxia of speech. Brain 137(10):2783–2795PubMedPubMedCentral

Duffy JR (2006) Apraxia of speech in degenerative neurologic disease. Aphasiology 20(6):511–527

Josephs KA et al (2005) Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase 11(4):283–296PubMed

Josephs KA et al (2012) Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. Brain 135(5):1522–1536PubMedPubMedCentral

Josephs KA et al (2006) Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 129(6):1385–1398PubMed

Whitwell JL et al (2019) An evaluation of the progressive supranuclear palsy speech/language variant. Mov Disord Clin Pract 6(6):452–461PubMedPubMedCentral

Tetzloff KA et al (2018) Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. Neurocase 24(2):111–120PubMedPubMedCentral

Utianski RL et al (2018) Clinical progression in four cases of primary progressive apraxia of speech. Am J Speech Lang Pathol 27(4):1303–1318PubMedPubMedCentral

10.

Marshall VL et al (2009) Parkinson’s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 24(4):500–508PubMed

11.

Seifert KD, Wiener JI (2013) The impact of DaTscan on the diagnosis and management of movement disorders: a retrospective study. Am J Neurodegener Dis 2(1):29–34PubMedPubMedCentral

12.

Pirker W et al (2000) [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 15(6):1158–1167PubMed

13.

Klaffke S et al (2006) Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord 21(10):1724–1727PubMed

14.

Im JH et al (2006) Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson’s disease: analysis with [(123)I]IPT single photon emission computed tomography. J Neurol Sci 244(1–2):103–109PubMed

15.

McKhann G et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34(7):939–944PubMed

16.

McKeith IG et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65(12):1863–1872PubMed

17.

Neary D et al (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51(6):1546–1554PubMed

18.

Litvan I et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47(1):1–9PubMed

19.

Boeve BF, Lang AE, Litvan I (2003) Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 54(5):S15–S19PubMed

20.

Gilman S et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9):670–676PubMedPubMedCentral

21.

Brooks BR et al (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293–299PubMed

22.

Duffy JR, Strand EA, Josephs KA (2014) Motor speech disorders associated with primary progressive aphasia. Aphasiology 28(8–9):1004–1017PubMed

23.

Nasreddine ZS et al (2005) The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695–699PubMed

24.

Hoglinger GU et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32(6):853–864PubMedPubMedCentral

25.

Whitwell JL et al (2011) Clinical correlates of white matter tract degeneration in progressive supranuclear palsy. Arch Neurol 68(6):753–760PubMedPubMedCentral

26.

Goetz CG et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129–2170PubMed

27.

Kertesz A, Davidson W, Fox H (1997) Frontal behavioral inventory: diagnostic criteria for frontal lobe dementia. Can J Neurol Sci 24(1):29–36PubMed

28.

Strauss SA (1998) An unusual case of wrongful pregnancy: liability of doctor resulting from misrepresentation. Med Law 17(1):7–11PubMed

29.

Maltais DD et al (2020) Confirmation of (123)I-FP-CIT-SPECT (ioflupane) quantification methods in dementia with Lewy body and other neurodegenerative disorders. J Nucl Med 2020:119

30.

Antonini A et al (2003) 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci 24(3):149–150PubMed

31.

Badoud S et al (2016) Discriminating among degenerative parkinsonisms using advanced (123)I-ioflupane SPECT analyses. Neuroimage Clin 12:234–240PubMedPubMedCentral

32.

Iranzo A et al (2017) Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol 82(3):419–428PubMed

33.

Stephenson D et al (2019) The qualification of an enrichment biomarker for clinical trials targeting early stages of Parkinson’s disease. J Parkinsons Dis 9(3):553–563PubMedPubMedCentral

34.

Nicastro N, Burkhard PR, Garibotto V (2018) Scan without evidence of dopaminergic deficit (SWEDD) in degenerative parkinsonism and dementia with Lewy bodies: a prospective study. J Neurol Sci 385:17–21PubMed

35.

Marek K et al (2014) Longitudinal follow-up of SWEDD subjects in the PRECEPT study. Neurology 82(20):1791–1797PubMedPubMedCentral

36.

Josephs KA et al (2013) Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA. Neurology 81(4):337–345PubMedPubMedCentral

37.

Utianski RL et al (2018) Prosodic and phonetic subtypes of primary progressive apraxia of speech. Brain Lang 184:54–65PubMedPubMedCentral

Title: Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech
Authors: Zeynep Idil Seckin
Jennifer L. Whitwell
Rene L. Utianski
Hugo Botha
Farwa Ali
Joseph R. Duffy
Heather M. Clark
Mary M. Machulda
Lennon G. Jordan
Hoon-Ki Min
Val J. Lowe
Keith A. Josephs
Publication date: 01-09-2020
Publisher: Springer Berlin Heidelberg
Keywords: Apraxia
Progressive Supranuclear Palsy
Published in: Journal of Neurology / Issue 9/2020
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-09883-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech

Abstract

Objective

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2020

Cerebellar degeneration in adult spinal muscular atrophy patients

A novel frameshift deletion in autosomal recessive SBF1-related syndromic neuropathy with necklace fibres

Pick’s disease: clinicopathologic characterization of 21 cases

A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid β-amyloid42, total-tau, phospho-tau and α-synuclein in the differential diagnosis of neurodegenerative dementia

Application of “Mentzer’s PML case definition” to natalizumab-treated patients in the setting of strict MRI-based pharmacovigilance

Miller–Fisher-like syndrome related to SARS-CoV-2 infection (COVID 19)